DUOSTIM and AI: is There a Difference Between Oocyte Performance in the Follicular and Luteal Phases?

January 23, 2025 updated by: Yuri Ian Lima Alves de Oliveira, Rio de Janeiro State University
In vitro fertilization (IVF) has revolutionized assisted reproductive techniques, bringing hope to thousands of people seeking to fulfill their dream of parenthood. However, patients with low ovarian reserve face additional challenges, such as limited response to ovarian stimulation and difficulty in obtaining good-quality eggs. Innovative protocols such as Duostim (dual stimulation) have shown promise in these cases, allowing the maximum number of eggs to be retrieved in a short period of time. In addition, technological advances in the analysis of the quality of mature eggs, such as the use of the Magenta tool, are transforming the way specialists evaluate and select the best gametes to increase the chances of success. This article explores how these approaches complement each other, offering new possibilities for patients with low ovarian reserve and raising the standards of reproductive medicine.

Study Overview

Status

Completed

Conditions

Detailed Description

The analysis of the two stimulation phases in a Duostim protocol for IVF using the Magenta tool may have significant clinical relevance, especially in the context of patients with low ovarian reserve or who require optimization in the number of embryos available in IVF cycles in a short period of time. The Magenta tool, being based on AI and machine learning, can identify patterns related to the quality of oocytes and embryos obtained in both phases. This can help determine if there are significant differences in embryo competence between oocytes collected in the follicular phase and the luteal phase. Magenta-powered analysis can provide robust data to validate the Duostim protocol, identify subgroups that benefit most from it, and promote greater clinical efficiency in IVF treatments, especially in challenging cases. This approach can revolutionize the way personalized protocols are designed and monitored to maximize reproductive success. The aim of this study is to compare the two phases of ovarian stimulation - follicular and luteal - in patients undergoing the Duostim protocol, using the Magenta tool for detailed analysis of mature eggs obtained in each phase. The research seeks to identify differences in oocyte quality between the two stages, as well as to evaluate the efficiency of the protocol in maximizing results in patients with low ovarian reserve.

Study Type

Observational

Enrollment (Actual)

92

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • RJ
      • Rio de Janeiro, RJ, Brazil, 22793-080
        • Vida - Medicina Reprodutiva

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Women of reproductive age undergoing ovarian stimulation for in vitro fertilization (IVF)

Description

Inclusion Criteria:

  • Patients undergoing IVF with DUOSTIM protocol and Magenta analysis of mature eggs.

Exclusion Criteria:

  • Canceled Duostim Magenta IVF cycles

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
DuoStim1
Follicular phase Stimulation
DuoStim2
Luteal Phase stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Follicular and luteal phase oocytes Magenta score
Time Frame: 30 days
Assessment of oocyte potential to generate blastocysts at two different times of oocyte retrieval
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rio de Janeiro State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2024

Primary Completion (Actual)

January 15, 2025

Study Completion (Actual)

January 15, 2025

Study Registration Dates

First Submitted

January 23, 2025

First Submitted That Met QC Criteria

January 23, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 23, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • VD001/2025

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe